echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Since the beginning of this year, this pharmaceutical company has transferred the equity of 4 holding companies

    Since the beginning of this year, this pharmaceutical company has transferred the equity of 4 holding companies

    • Last Update: 2021-12-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Kang Enbei issued an announcement stating that the transfer of 42% of the shares of the subsidiary Cherish Ming, the current consortium consisting of five companies including Zhongsheng Pharmaceutical will be transferred with a total consideration of 1.
    68 billion yuan
    .
    Specifically, on December 2, Conba received the "Listing Project Information Feedback Letter" issued by the Zhejiang Equity Exchange.
    After the initial review of the bidding materials submitted by the intended transferee by the Zhejiang Equity Exchange, it complies with the transaction regulations The intended transferee is a consortium consisting of five companies: Fortunate Gem Limited, Huagai Xincheng Yuanhang, Anhui Traffic Holdings Jinshi Fund, Hainan Yuemu Minhan, and Zhongsheng Pharmaceutical.
    Let Zhenshiming's 30%, 4.
    75%, 4%, 2.
    5%, and 0.
    75% of the shares of Zhenshiming, and transfer a total of 42% of the shares of Zhenshiming.
    The transaction amount is estimated to be RMB 1.
    68 billion
    .
    Public information shows that in the first half of this year, Cherish Ming’s revenue was 509 million, and its contribution to Conba’s revenue was second only to the "Changyanning" series of products.
    In the same period, Cherish Ming’s net profit was close to 70 million, accounting for nearly three of the net profit of Kang Enbei’s return to mothers.
    One part
    .
    From the overall point of view, the importance of cherishing the Ming can be said to be self-evident
    .
    However, this time Kang Enbei still decided to "break away".
    According to the announcement, the main purpose is to focus on the core business of the traditional Chinese medicine health industry and promptly dispose of inefficient assets and withdraw funds
    .
    It is reported that after preliminary calculations, if the equity transfer is completed at the listed reserve price, it is expected to increase Conba’s net profit by approximately 2.
    3 billion yuan, which will have a significant positive impact on Conba’s performance
    .
    It is worth noting that since this year, Conba has been busy selling equity and assets in order to release equity pledges, focus on core businesses, promptly dispose of inefficient assets, and withdraw funds; it is reported that Conba has already sold shares before this transaction.
    After transferring the equity of a number of holding companies
    .
    For example, on November 29, Kang Enbei issued an announcement stating that it would publicly transfer 25% of the shares of Dear Pharmaceuticals
    .
    The content of the announcement shows that the transfer is to focus on the development of the company’s core business of the traditional Chinese medicine health industry, timely disposal of inefficient assets, and withdrawal of funds.
    Zhejiang Jinhua Kangenbei Biopharmaceutical Co.
    , Ltd.
    "Bei") intends to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
    , Ltd.
    (hereinafter referred to as "Dear Pharmaceutical") held by Zhejiang Equity Exchange through public listing
    .
    According to the assessment, the assessed value of Jinhua Kangenbei's 25% equity stake in Dier Pharmaceutical is RMB 39,747,228.
    58
    .
    On August 13, Kang Enbei issued an announcement stating that the board of directors agreed to the company’s transfer of 100% equity of Guizhou Beite Pharmaceutical Co.
    , Ltd.
    through public listing in Zhejiang Equity Exchange; a supplementary announcement was issued on November 6 stating that the initial listing period had not expired.
    Intentional transferees who have solicited equity
    .
    On June 12, Conba Pharmaceutical Co.
    , Ltd.
    intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
    , Ltd.
    held by the Zhejiang Equity Exchange through a public listing.
    The transfer was completed at a price of 53.
    37 million yuan.
    Let, on October 28, complete the registration procedures for industrial and commercial changes
    .
    In addition, in addition to the transfer of equity, Conba has actually released a number of pledges and returned the raised funds recently
    .
    In this regard, the industry believes that Conba’s move to revitalize funds through the transfer has achieved results
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.